HTT and Huntington disease: The systemic administration of siRNA targeted to huntingtin gene (Htt) mRNA bound with brain-targeted microvesicles via the GAPDH–TARBP2 approach provided an almost 40% decrease in Htt mRNA, at least in the brain cortex of mice, modeling Huntington’s disease.